INTRODUCTION
Two cannabinoid receptor subtypes, both G protein-linked, have been isolated and cloned to date; the CB 1 receptor is found mainly in the central nervous system and some peripheral nerve terminals and the CB 2 receptor is associated mainly with immune tissues (Pertwee, 1999) . There is evidence, however, that the cannabinoid receptor classification is incomplete.
There are data which suggest the presence of multiple CB 1 subtypes in the spinal cord (Welch et al., 1998) and putative CB 2 -like receptors have been implicated in antinociceptive and hypotensive effects of cannabinoid agonists (Hanuš et al., 1999; Calignano et al., 2001) .
Experiments using CB receptor knockout mice have uncovered a putative novel cannabinoid receptor in the mouse brain (Breivogel et al, 2001; Di Marzo et al., 2000; Hájos et al., 2001; Monory et al., 2002) . In addition, studies of the rat mesentery have described a novel anandamide-sensitive, SR141716A-sensitive endothelial receptor (Járai et al., 1999) .
Recently, Zygmunt et al. (2002) reported that ∆ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) induce a CB 1 /CB 2 independent release of calcitonin gene-related peptide (CGRP) from capsaicin-sensitive nerves in isolated rat mesenteric arterial rings that could be blocked by the vanilloid receptor (TRPV1) blocker ruthenium red but that was still present in TRPV1 knockout animals.
Capsaicin-sensitive sensory nerves are widely distributed in the cardiovascular system and have a dual function; an afferent function whereby they participate in reflex activation of motor nerves, and an efferent function, whereby neurotransmitter is released from the nerve terminal being stimulated (Maggi & Meli, 1988) . Studies on dorsal root ganglia (DRG) and F-11 cells (DRG x neuroblastoma hybridomas) indicate that both CB 1 and CB 2 receptor proteins exist in these cells (Ross et al., 2001) . However, only CB 1 receptors have been demonstrated to be transported from DRG cell bodies to the periphery of the sensory nerves (Hohmann & Herkenham, 1999) . Recently, functional evidence has been provided which suggests that non-CB 1 /CB 2 cannabinoid receptors are located on capsaicin-sensitive sensory nerves in the rat mesenteric bed (Ralevic & Kendall, 2001) . The potent cannabinoid CB 1 /CB 2 receptor agonist HU210 was found to attenuate sensory neurogenic relaxation evoked by electrical field stimulation (EFS) in preconstricted mesenteric beds. This inhibitory action was resistant to the CB 1 selective antagonists SR141716A and LY320135 and the CB 2 selective antagonist SR144528. HU210 had no effect on the vasorelaxant response to exogenous CGRP, suggesting prejunctional modulation of CGRP release (Ralevic & Kendall, 2001 ).
The present study investigated the effects of different classes of cannabinoid compounds represented by the aminoalkylindoles WIN55,212, and JWH-015, the bicyclic CP55,940 and the classical cannabinoid agonist THC, on sensory neurogenic vasorelaxation to EFS in the rat isolated mesenteric arterial bed. The effects of CB 1 (SR141716A, LY320135) and CB 2 (SR144528) selective antagonists on agonist responses were determined. Electrical stimulation of sensory nerve terminals releases CGRP, the principal sensory vasorelaxant in the rat isolated mesenteric arterial bed which can be reversed by the CGRP antagonist CGRP (Kawasaki et al., 1988; Han et al., 1990) . The effects of cannabinoids on responses to exogenous CGRP were, therefore, investigated in order to determine if the actions were mediated at a pre-or postjunctional site. Since there have been reported crosstalk between cannabinoid and vanilloid receptors, the actions of capsaicin in the presence of cannabinoids were investigated. Some of this work has been published in abstract form.
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METHODS

Mesenteric arterial bed preparation.
Male Wistar rats (250-300g) were killed by decapitation after exposure to CO 2 . Mesenteric beds were isolated and perfused via the superior mesenteric artery. The abdomen was opened and the superior mesenteric artery was exposed and cannulated with a blunted hypodermic needle. The superior mesenteric vein was cut, blood flushed from the preparation with 0.5 ml Krebs' solution and the gut dissected away from the mesenteric vasculature. The preparations were mounted on stainless steel grids (7 x 5 cm) in a humid chamber and perfused at a constant flow rate of 5 ml min -1 using a perfusion pump The resulting vasorelaxation response has been shown to be blocked by tetrodotoxin and capsaicin (Ralevic et al., 1991) consistent with it being mediated by capsaicin-sensitive sensory nerves (Kawasaki et al., 1988) . Moreover, the relaxation is mimicked by CGRP, whilst substance P and neurokinin A are inactive and vasoactive intestinal polypeptide (VIP) causes relaxation only at relatively high concentrations, and there are numerous CGRP-like immunoreactive fibres, but few substance P and VIP-like immunoreactive fibres present in the mesenteric arteries (Kawasaki et al., 1988) . In addition, the neurogenic relaxation to electrical field stimulation is abolished by the CGRP receptor antagonist CGRP(8-37) (Han et 
Experimental protocol.
Three consecutive relaxant response curves to EFS at 1-12 Hz, 'EFS control', 'EFS I', and 'EFS II', were generated in each preconstricted mesenteric arterial bed. The tone of the preparation was then allowed to return to preconstricted tone before the next stimulus was applied. The first response curve acted as a control, the compound under investigation was then added to the perfusate and after 15 min, response curves EFS I and EFS II were generated. Antagonists were added at the start of the equilibration period. Only a single concentration of agonist was used per preparation. In a separate series of experiments, a dose response curve was constructed to CGRP (0.05 pmol -0.5 nmol) and capsaicin (0.05 pmol - 
RESULTS
Effect of vehicle (0.01%) on vasorelaxant responses to EFS.
Electrical field stimulation (EFS 1-12 Hz, 0.1 ms, 60 V, 30 s) produced frequency-dependent relaxation of the rat isolated mesenteric arterial bed. Three frequency-response curves were constructed, EFS control, EFS I and EFS II. The first curve acted as a control, the compound under investigation was added for 15 min, then a further two curves were constructed. The equivalent concentration of the drug vehicle (0.01% ethanol) had no effect on the vasorelaxant response (Fig. 1a) , demonstrating that the frequency response curves are reproducible under control conditions (EFS control 51.7 ± 6.3 and EFS II 43.3 ± 5.8; P>0.05).
Effect of SR141716A (1 µ M) on vasorelaxant responses to EFS.
SR141716A has previously been reported to augment sensory neurogenic relaxations to EFS in the rat isolated arterial mesenteric bed (Ralevic & Kendall, 2001) . In this study,
SR141716A
(1 µ M, n=9) was found to have no significant effect on the vasorelaxant response ( Fig. 1b) , at a submaximal frequency of 8 Hz (EFS control 54.7 ± 5.4%, EFS I 48.6 ± 5.8 and EFS II 45.3 ± 6.1; P>0.05). The R MAX was unaffected; EFS control from 56.0 ± 4.8% to EFS II 48.5 ± 5.9%. SR141716A had no significant effect on the tone of the preparations.
Effect of LY320135 (1 µ M) on vasorelaxant responses to EFS.
The experiments were carried out in the presence of LY320135 (1 µ M, n=3) to determine if the antagonist had any effect on the vasorelaxant response to EFS. At a submaximal frequency of 8 Hz LY320135 had no effect on the vasorelaxant response ( unaffected; EFS control from 66.4 ± 5.8% to EFS II 56.7 ± 4.2%. LY320135 had no significant effect on the tone of the preparations.
Effect of SR144528 (1 µ M) on vasorelaxant responses to EFS.
In order to rule out any involvement of CB 2 receptors, the experiments were repeated in the presence of the CB 2 antagonist SR144528 (1µM, n=3, Fig. 1d ). At a submaximal frequency of 8 Hz SR144528 had no effect on the vasorelaxant response (EFS control 68.8 ± 7.2%, EFS I 64.2 ± 4.2 and EFS II 57.5 ± 2.5; P>0.05). The R MAX was reduced slightly but significantly;
EFS control from 80.3 ± 2.4%, EFS I 71.5 ± 0.8% and EFS II 66.3 ± 2.4% (P<0.05).
SR144528 had no significant effect on the tone of the preparations.
Effect of WIN55,212 on vasorelaxant responses to EFS.
WIN55,212, a high potency cannabinoid agonist at both CB 1 and CB 2 receptors, attenuated to EFS II 33.0 ± 5.1%. WIN55,212 had no significant effect on the tone of the preparations.
Effect of SR141716A and SR144528 on the inhibitory actions of WIN55,212 on the vasorelaxant response to EFS.
In order to determine if the inhibitory actions exerted by WIN55,212 were mediated by either 
Effect of the WIN55,212 stereoisomer (-)WIN55,212 on vasorelaxant responses to EFS.
The stereoisomer, (-)WIN55,212, was used to investigate if a stereospecificity for this compound exists; this is a useful tool to determine if the actions are receptor-mediated (Fig.   5 ). 1 µ M (-)WIN55,212 had no significant effect on the sensory neurogenic vasorelaxation evoked by EFS, at 8 Hz EFS control 63.0 ± 7.8% and EFS II 51.2 ± 9.0%; n=6, P>0.05).
Effect of CP55,940 on vasorelaxant responses to EFS.
CP55,940, an agonist which has equivalent high potency at both CB 1 and CB 2 receptor subtypes, attenuated sensory neurogenic relaxations in a concentration-dependent manner (Fig. 6) . At a concentration of 0.01 µ M, CP55,940 blocked relaxation only at 8 Hz but had no effect on the maximal relaxation (R MAX ). 
Effect of JWH-015 on vasorelaxant responses to EFS.
To further characterise the receptor involved in the inhibition of the neurogenic response the CB 2 selective agonist JWH-015 was investigated (Fig. 8a, b) . At a concentration of 0.1 µM JWH-015, there was no significant difference between the frequency-response curves or the (Fig. 8c, d 
Effect of THC on vasorelaxant responses to EFS.
The classical plant-derived cannabinoid THC, which acts as a partial agonist at both CB 1 and CB 2 receptors, attenuated sensory neurogenic relaxation (Fig. 9a, b) . In the presence of 0.1 µM THC, at a submaximal frequency of 8 Hz, the response was reduced from EFS control 60.6 ± 7.6% to EFS II 31.1 ± 3.9% (n=6, P<0.05). 1 µ M THC reduced 8 Hz EFS control 53.1 ± 5.0% to EFS II 11.1 ± 1.6%. The maximal response was also significantly reduced, from 59.3 ± 7.5% to 17.3 ± 2.0% (n=4, P<0.05). THC initially produced a transient pressor effect (30.14 ± 2.6 mmHg) followed by a reduction in the tone of the preparation. The secondary vasorelaxation required methoxamine to maintain tone.
Effect of SR141716A and SR144528 on inhibition by THC of the vasorelaxant response to EFS.
DISCUSSION
The present study has shown that cannabinoid agonists representative of three different chemical classes attenuate sensory neurogenic relaxation elicited by EFS in the rat isolated mesenteric arterial bed. The presence of a cannabinoid-sensitive site on sensory nerves is in agreement with previous studies by Richardson et al., and Ellington et al., in which CP55, 940 and anandamide were demonstrated to inhibit capsaicin-evoked CGRP release in rat paw skin, which is richly innervated with sensory nerves, in a SR141716A-sensitive manner (Richardson et al., 1998b , Ellington et al., 2002 . Furthermore, studies using 3 H-CP55,940 in radioligand binding assays have uncovered a saturatable binding site using the trigeminal ganglia as a model for sensory nerves (Richardson et al., 1998a) . This would indicate that a CP55,940-sensitive receptor is present on sensory nerves, in agreement with the functional pharmacological studies. CB 1 mRNA has been located in DRG cells, and CB 1 receptors are trafficked to peripheral sensory nerve terminals (Hohmann & Herkenham, 1999) and so cannabinoids would be expected to exert their inhibitory effects by prejunctional modulation of neurotransmitter release from the peripheral nerve terminal. This is in agreement with our findings that none of the cannabinoids investigated exerted an inhibitory effect on vasorelaxation in response to exogenous CGRP.
The concentrations of cannabinoid agonist used in this study are in the micromolar range, much higher than concentrations used in some other bioassay preparations such as mouse vas deferens and CB receptor-transfected cell lines (Pertwee, 1999; Howlett et al., 2002) .
However, the concentrations used were in agreement with previous studies on isolated blood vessels (White & Hiley, 1998) . Since cannabinoids are highly lipophilic compounds, the true concentration at the site of action could be much lower than the micromolar range. Indeed, the time-dependency of the inhibitory action (EFS II more sensitive to the inhibitory actions than EFS I) could be, in part, due to the slow diffusion of the compounds through the blood vessel wall.
The inhibitory actions of both WIN55,212 and CP55,940 in the rat mesenteric bed, which were selectively antagonised by CB 1 but not CB 2 antagonists, indicate the likely involvement of CB 1 or CB 1 -like receptors. Neither of the two compounds are agonists at TRPV1 receptors (Zygmunt et al., 1999) . Moreover, the inactivity of the stereoisomer (-)WIN55,212 indicates a clear structure activity relationship. Whilst we cannot rule out the possibility that, at least part of the action of SR141716A was due to functional antagonism (Ralevic & Kendall, 2001 ), this is unlikely to account for all its inhibitory actions as another CB 1 antagonist LY320135, was similarly effective. However, there is growing evidence indicating the existence of novel cannabinoid receptors. Indeed, WIN55,212 is reported to be active at the putative novel cannabinoid receptor identified in the brain. This receptor, described by Breivogel et al (2001) was SR141716A-sensitive, whereas the novel WIN55,212-sensitive receptors reported by Hájos et al. (2001) and Monory et al. (2002) were SR141716A-resistant. Our data describing the effects of the other cannabinoid agonists, suggest that CB 1 /CB 1 -like receptors are not the only subtype expressed on the perivascular sensory nerves.
JWH-015, a CB 2 selective agonist, inhibited sensory neurogenic vasorelaxation, which was unexpected as there is little evidence for the expression of CB 2 receptors in sensory nerves.
However, this action was not blocked by a selective CB 2 antagonist SR144528. Griffin et al., (1997) reported that JWH-015 inhibited electrically evoked contractions in the mouse vas deferens and the guinea-pig myenteric plexus and that this effect could be reversed by SR141716A in the myenteric plexus, suggesting that the inhibitory actions are CB 1 -mediated (Griffin et al., 1997) . This is in agreement with our study in that the inhibitory actions of JWH-015 appeared to be attenuated in the presence of the CB 1 antagonist SR141716A.
Recently, Ross et al, (2001) , described CB 2 receptor protein in F-11 (DRG x neuroblastoma hybridoma) cells using antibodies raised against the N-terminus. However, in nerve ligation studies using antisense cRNA probes, mRNA for CB 2 receptors could not be detected in the DRG and CB 2 receptors were not found to be transported to peripheral nerve endings (Hohmann & Herkenham, 1999) . Thus, the pharmacological and molecular studies do not indicate expression of CB 2 receptors in sensory nerves. There is evidence for cardiovascular actions of CB 2 receptors as HU-308, a bicyclic CB 2 specific agonist has been shown to significantly reduce blood pressure in vivo and this action can be blocked by the CB 2 antagonist SR144528 (Hanuš et al.,1999) . Therefore, a novel JWH-015-sensitive, SR144528-resistant cannabinoid receptor could be involved in the regulation of perivascular sensory nerves. However, an indirect action cannot be ruled out; JWH-015 could be activating cannabinoid receptors and releasing vasoactive mediators from cells associated with sensory nerves such as mast cells, which have been reported to express CB 2 receptors, although these inhibitory effects were SR144528-sensitive (Facci et al., 1995) .
THC, a plant-derived cannabinoid that acts equally well at both CB receptor subtypes, also inhibited vasorelaxation to EFS. This effect could not be blocked by either SR141716A or SR144528. A postjunctional effect was ruled out, as THC had no effect on CGRP vasorelaxation. It is, therefore, possible that THC is mediating its inhibitory actions via a novel prejunctional cannabinoid receptor. In contrast to the other cannabinoids investigated, THC produced a vasoconstriction when added to the perfusate; this is not unexpected as THC has been reported to produce a pressor response followed by a prolonged hypotension in vivo (Wagner et al., 1998) . The hypotensive effect can be abolished by surgical/pharmacological removal of sympathetic tone and this effect is also sensitive to SR141716A, leading to the possibility of sympatho-inhibition by presynaptic CB 1 receptors. The pressor response could This article has not been copyedited and formatted. The final version may differ from this version. not be abolished by the elimination of sympathetic tone and so is thought to be due to a peripheral vasoconstriction; it is therefore possible, that the constriction we observed in the mesenteric bed contributes to the pressor effect observed in vivo. Vasoconstriction is unlikely, however, to have caused a functional antagonism of the neurogenic relaxation responses, as it was not sustained (the relaxation response curves were generated after reversal of the constriction) and, as relaxation responses to CGRP were unaffected.
THC and cannabidiol have recently been described as acting via a novel receptor subtype to release CGRP in capsaicin-sensitive sensory nerves (Zygmunt et al., 2002) . The ability of THC to release CGRP was blocked by the vanilloid blocker ruthenium red, but was present in TRPV1 knockout mice, which raises the possibility of THC activating a transient receptor potential (TRP) ion channel to release CGRP. It is possible that the constriction we observed to THC could mask the effect of the co-incident CGRP release and, indeed, a relaxation followed. Thus, vasorelaxation to EFS could be attenuated because the sensory nerves were depleted of CGRP, or the CGRP receptors were desensitised; this would explain why the inhibitory action could not be blocked by SR141716A. However, ruthenium red (1 µ M) does not block the inhibitory actions of THC on sensory neurotransmission in the rat isolated mesenteric arterial bed (Duncan et al., 2003) , so a vasorelaxant mechanism dependent on CGRP depletion is unlikely. Interestingly, Zygmunt et al., did not report a constrictor effect of THC, but their study was carried out in arterial segments, whereas the present experiments were in whole vascular beds, so more complex mechanisms could be involved such as the release of endothelial vasoconstrictors.
From the data presented, THC appears to mediate the inhibition of sensory neurotransmission via a non-CB 1 CB 2 site. The apparently differential sensitivities of JWH-015 and THC to the actions of SR141716A would suggest they are not acting at a common site. We recently reported that the inhibitory actions of the putative endocannabinoid noladin ether on sensory neurotransmission could not be blocked by CB 1 and CB 2 antagonists (Duncan et al., 2004) , or ruthenium red (Duncan et al., 2003) , but could be abolished by the pretreatment of animals with pertussis toxin (PTX). The inhibitory actions of THC are also abolished by PTXpretreatment (unpublished observations). Thus, there does appear to be a Gi/o proteincoupled, cannabinoid-sensitive receptor on the capsaicin-sensitive perivascular sensory nerves.
In this study, the antagonists alone had no effect on mesenteric arterial contraction, indicating a potential lack of effect of endogenous cannabinoid tone as a modulator in the vascular beds.
This is in contrast with a previous report from this laboratory showing that SR141716A
augmented sensory neurotransmission in the same model (Ralevic & Kendall, 2001 ). The reason for this is not clear as the sex, strain and ages of the rats, and the experimental conditions were similar.
In the investigation of possible cross-talk between the cannabinoid and vanilloid systems, we found no modulation of the capsaicin response by CP55,940, THC and JWH-015.
WIN55,212 enhanced the capsaicin response, for reasons which are not clear (but which are unrelated to its inhibitory effects on electrically-evoked sensory neurotransmitter release), indicating possible complex effects of this compound on sensory nerves.
In conclusion, it is not possible to fully characterise the receptors involved in cannabinoidmediated attenuation of sensory nerve mediated vasorelaxation using the antagonists presently available, and the inhibitory prejunctional effects cannot be readily characterised as CB 1 or CB 2 mediated. However, we propose that a heterogeneous population of cannabinoid receptors exist on capsaicin-sensitive nerves in the rat mesenteric bed. Our findings suggest at This article has not been copyedited and formatted. The final version may differ from this version. 
